B. Riley Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

B. Riley Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,735	Closed	-$154K	–	566
2019 Q4	$154K	Buy	15,735 +100	+0.6%	+$893	0.02%	374
2019 Q3	$108K	Buy	15,635 +2,550	+19%	+$19.5K	0.02%	369
2019 Q2	$121	Buy	+13,085	New	+$158K	0.02%	375
2015 Q3	–	Sell	-1,949	Closed	-$115K	–	680
2015 Q2	$115K	Buy	1,949 +6	+0.3%	+$370	0.09%	248
2015 Q1	$121K	Sell	1,943 -454	-19%	-$26.4K	0.09%	253
2014 Q4	$137K	Buy	2,397 +1,684	+236%	+$93.8K	0.11%	215
2014 Q3	$34K	Sell	713 -1,627	-70%	-$86.2K	0.03%	492
2014 Q2	$122K	Buy	2,340 +109	+5%	+$5.57K	0.08%	313
2014 Q1	$118K	Buy	+2,231	New	+$103K	0.09%	285

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

B. Riley Wealth Management's TEVA Position: Q1 2020 in Review

B. Riley Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2020, closing a stake of 15,735 shares — an estimated $154K sold.

B. Riley Wealth Management first reported a position in TEVA in Q1 2014 and held it in 9 quarters. The position peaked at $154K in Q4 2019. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

B. Riley Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
B. Riley Wealth Management sold 15,735 Teva Pharmaceuticals shares in Q1 2020, an estimated $154K.
B. Riley Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 9 quarters.
B. Riley Wealth Management's Teva Pharmaceuticals position peaked at $154K in Q4 2019.
459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on B. Riley Wealth Management's 13F filing for Q1 2020, filed 15 May 2020.